Curaleaf International, the largest vertically integrated cannabis company in Europe and a subsidiary of Curaleaf Holdings, has acquired Can4Med, a top pharmaceutical wholesaler in Poland that specializes in cannabinoid medications, marking a significant advancement in its mission to improve patient access to medical cannabis throughout Europe.
Context of the Purchase
Poland offers a favorable environment for the industry’s expansion and innovation because it has one of the biggest patient populations in all of Europe looking for medical cannabis. Curaleaf International’s strategic decision to collaborate with Can4Med demonstrates its dedication to satisfying the region’s rising need for premium medical cannabis products.
At Curaleaf, Matt Darin serves as CEO. He declared:
“Curaleaf International has advanced significantly with this acquisition. The medical cannabis industry in Poland is growing quickly, and we are able to better assist patients while promoting expansion throughout Europe thanks to our collaboration with Can4Med.”
Can4Med is an authority in the pharmaceutical wholesale and retail distribution of cannabinoid-containing products, including medicinal cannabis. So, it is in a postion to play a crucial role in ensuring patients in Poland have access to safe and effective treatments. Curaleaf International’s pharmaceutical wholesaler licence, which allows for the marketing and distribution of drugs for medicinal reasons, gives the company a strong platform on which to grow its product line and better meet the needs of patients in the area.
“We are overjoyed that Can4Med, a trailblazing player in Poland’s cannabis industry, has partnered with Curaleaf, the world’s foremost cannabis company. Can4Med founder Maximilian Weinberg stated, “This acquisition represents a critical turning point in our journey, guaranteeing an unmatched supply chain that positions us to meet and exceed the demands of the entire Polish market.”
Possibilities for Polish medical cannabis market
The Polish Pharmaceutical Chamber projects that the country may have up to 300,000 medical cannabis users, and that by 2026, there would be 1.3 million legal cannabis users (medical and CBD combined). A network of medical experts authorized to prescribe cannabis is facilitating this upward trajectory. Everything points to an increasing recognition of its healing advantages.
Poland had a notable uptick in the usage of medicinal cannabis in 2023, dispensing over 3,000 kg of the drug and indicating a substantial change in public perceptions of its application. The registration procedure in Poland is not without its complications for both patients and producers. Curaleaf International, on the other hand, has become a major licensed producer in the Polish market through its subsidiary Four 20 Pharma GmbH.
Leading the European cannabis market could be Poland. As a result, Curaleaf International’s acquisition of Can4Med enhances its standing as a reliable supplier of medications derived from cannabis. It will be able to spur innovation and expansion in the area while attending to the changing demands of patients. This alliance, with its common dedication to quality, accessibility, and patient care, heralds in a new era of opportunities for both businesses and their clientele.